CoChat

Dynamic Changes in Circulating Tumor DNA During Immunotherapy for Head and Neck Cancer: SHIZUKU-HN Study

Open access

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Immune checkpoint inhibitors (ICIs) are effective in treating recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), but only 20% of patients achieve durable responses. This study evaluated circulating tumor DNA (ctDNA) as a real-time biomarker for monitoring treatment response in HNSCC. The SHIZUKU-HN study prospectively collected and analyzed serial plasma samples (n = 27) from HNSCC patients undergoing ICIs, using Guardant360 to assess ctDNA variant allele frequency (VAF) and genetic mutations. Tumor volumes were quantified using 3D reconstruction of CT scans, and data from Japan’s C-CAT database (n = 2255) provided insights into ctDNA testing in HNSCC. C-CAT data showed that ctDNA testing was underutilized, performed in only 7% of head and neck cancer cases. In SHIZUKU-HN, mean VAF significantly correlated with tumor volume (Spearman’s ρ = 0.70, p = 0.001), often preceding radiographic progression. BRAF and APC mutations disappeared in partial responders, while GNAS mutations varied. EGFR and PIK3CA amplifications, detectable via ctDNA but missed in tissue biopsies, indicated emerging resistance mechanisms. The SHIZUKU-HN study demonstrates the potential of ctDNA as a dynamic biomarker in HNSCC, offering early insights into treatment efficacy and informing personalized ICI therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms26010235

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (a) Distribution of panel tests based on tissue (blue) and blood (red) samples in the C-CAT database. (b) Representation of the head and neck squamous cell carcinoma (HNSCC) cohort within the C-CAT database. (c) Frequently detected gene variants in tissue and blood samples from HNSCC cases. CGP, comprehensive genomic profiling; C-CAT, Cancer Center for Advanced Cancer Genome Therapy; HNC, head and neck cancer; HNSCC, head and neck squamous cell carcinoma.
Figure 1 (a) Distribution of panel tests based on tissue (blue) and blood (red) samples in the C-CAT database. (b) Representation of the head and neck squamous cell carcinoma (HNSCC) cohort within the C-CAT database. (c) Frequently detected gene variants in tissue and blood samples from HNSCC cases. CGP, comprehensive genomic profiling; C-CAT, Cancer Center for Advanced Cancer Genome Therapy; HNC, head and neck cancer; HNSCC, head and neck squamous cell carcinoma.CC BY · PubMed Central
Figure 2 Correlation Between ctDNA and tumor volume, and comparison with tissue-based analysis. (a) Correlation between tumor volume (cm3), as determined by CT volumetric analysis, and mean VAF across 27 serial plasma samples from 10 patients. Pathogenic VAF (pVAF) represents VAF for pathogenic mutations, while all VAF (aVAF) includes all somatic mutations, encompassing variants of unknown significance (VUS) and synonymous mutations. (b) CtDNA dynamics for each gene variant, alongside the corresponding radiographic response, illustrated for a progressive disease case (HN05). Asterisks on CT images indicate target lesions. (c) Spider plot depicting mean VAF dynamics during ICI treatment, with color-coded radiographic responses: PD (red), SD (green), and PR (yellow). VAF, variant allele frequency; VUS, variants of unknown significance.
Figure 2 Correlation Between ctDNA and tumor volume, and comparison with tissue-based analysis. (a) Correlation between tumor volume (cm3), as determined by CT volumetric analysis, and mean VAF across 27 serial plasma samples from 10 patients. Pathogenic VAF (pVAF) represents VAF for pathogenic mutations, while all VAF (aVAF) includes all somatic mutations, encompassing variants of unknown significance (VUS) and synonymous mutations. (b) CtDNA dynamics for each gene variant, alongside the corresponding radiographic response, illustrated for a progressive disease case (HN05). Asterisks on CT images indicate target lesions. (c) Spider plot depicting mean VAF dynamics during ICI treatment, with color-coded radiographic responses: PD (red), SD (green), and PR (yellow). VAF, variant allele frequency; VUS, variants of unknown significance.CC BY · PubMed Central
Figure 3 Study design and sequencing outcomes at our institution. (a) Detected plasma variants through next-generation sequencing (NGS), color-coded by ICI response, sample collection point, and type of genetic alteration. (b,c) Dynamic ctDNA patterns for each gene variant and the corresponding radiographic response, highlighting HN01 and HN12, which demonstrated partial response (PR). HN03 showed progressive disease (PD). Asterisks on CT images indicate target lesions. HN01 is shown as a PET/CT image to clarify tumor lesions. R/M HNSCC, recurrent/metastatic head and neck squamous cell carcinoma; NGS, next-generation sequencing.
Figure 3 Study design and sequencing outcomes at our institution. (a) Detected plasma variants through next-generation sequencing (NGS), color-coded by ICI response, sample collection point, and type of genetic alteration. (b,c) Dynamic ctDNA patterns for each gene variant and the corresponding radiographic response, highlighting HN01 and HN12, which demonstrated partial response (PR). HN03 showed progressive disease (PD). Asterisks on CT images indicate target lesions. HN01 is shown as a PET/CT image to clarify tumor lesions. R/M HNSCC, recurrent/metastatic head and neck squamous cell carcinoma; NGS, next-generation sequencing.CC BY · PubMed Central
Figure 4 Timing of plasma collection and body tumor volume estimation. (a) Patients monitored by ctDNA analysis at our institution; 12 patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who received immune checkpoint inhibitors (ICIs) were enrolled; 2 patients were excluded due to inadequate baseline samples. (b) Plasma ctDNA analysis using Guardant360. Plasma samples were obtained before ICI infusion (baseline), at 4 weeks, 6 months, or at progression of disease (PD). (c) Tumor volume measurement using computed tomography (CT) volume analysis on an image analysis workstation (syngo.via). Tumor contours were set in the axial and sagittal planes as shown. ctDNA, circulating tumor DNA; ICIs, immune checkpoint inhibitors; CT, computed tomography.
Figure 4 Timing of plasma collection and body tumor volume estimation. (a) Patients monitored by ctDNA analysis at our institution; 12 patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who received immune checkpoint inhibitors (ICIs) were enrolled; 2 patients were excluded due to inadequate baseline samples. (b) Plasma ctDNA analysis using Guardant360. Plasma samples were obtained before ICI infusion (baseline), at 4 weeks, 6 months, or at progression of disease (PD). (c) Tumor volume measurement using computed tomography (CT) volume analysis on an image analysis workstation (syngo.via). Tumor contours were set in the axial and sagittal planes as shown. ctDNA, circulating tumor DNA; ICIs, immune checkpoint inhibitors; CT, computed tomography.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 12

Metadata

Authors
Noji, R., Tohyama, K., Nakamura, S., Naito, T., Oikawa, Y., Kuroshima, T., Tomioka, H., Michi, Y., Ikeda, S., Asakage, T., Miura, M., Hamamoto, Y., Harada, H., & Kano, Y.
Affiliations
Institute of Science Tokyo (JP)
Corresponding author
Kano, Yoshihito
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2024-12-30
Volume
26
Issue
1
Pages
235
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4405920634
Cited by
11
References
41
Citations by year
2026: 6 · 2025: 5
FWCI
2.21
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • JSPS KAKENHI (JP22K09680, JP21K10134, JP19K23909, JP22K21031)
  • TMDU Research Grant for the Utilization of Big Data (JP22K09680, JP21K10134, JP19K23909, JP22K21031)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords
circulating tumor DNA, head and neck squamous cell carcinoma, immune checkpoint inhibitors, liquid biopsy, variant allele frequency, treatment response monitoring, tumor volume, BRAF mutation, APC mutation, GNAS mutation, EGFR amplification, PIK3CA amplification, drug resistance
MeSH terms
Circulating Tumor DNA, Squamous Cell Carcinoma of Head and Neck, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Female, Head and Neck Neoplasms, Humans, Immunotherapy, Male, Middle Aged, Mutation, Prospective Studies, Biomarkers, Tumor, Class I Phosphatidylinositol 3-Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.